Table 2 Patient baseline demographic and clinical characteristics in cohort 2 (Apatinib plus Chemotherapy vs. Chemotherapy Alone)
| Â | Initial cohort | Â | Propensity-score-matched cohort | Â | |||||
|---|---|---|---|---|---|---|---|---|---|
|  | Apatinib plus Chemotherapy (n = 34) | Chemotherapy Alone (n = 97) | P |  | Apatinib plus Chemotherapy (n = 27) | Chemotherapy Alone (n = 27) | P | ||
Age, years | Â | Â | Â | Â | Â | Â | Â | ||
 < 50 | 15 (44.1) | 49 (50.5) | 0.658 |  | 13 (48.1) | 16 (59.3) | 0.585 | ||
 ≥ 50 | 19 (55.9) | 48 (49.5) |  |  | 14 (51.9) | 11 (40.7) |  | ||
ECOG PS at start | Â | Â | Â | Â | Â | Â | Â | ||
 0 | 5 (14.7) | 11 (11.3) | 0.833 |  | 3 (11.1) | 1 (3.7) | 0.603 | ||
 ≥ 1 | 29 (85.3) | 86 (88.7) |  |  | 24 (88.9) | 26 (96.3) |  | ||
Menopausal status at diagnosis | Â | Â | Â | Â | Â | Â | Â | ||
 Premenopausal | 23 (67.6) | 71 (73.2) | 0.691 |  | 19 (70.4) | 20 (74.1) | 1.000 | ||
 Postmenopausal | 11 (32.4) | 26 (26.8) |  |  | 8 (29.6) | 7 (25.9) |  | ||
Surgery on primary tumor | Â | Â | Â | Â | Â | Â | Â | ||
 Yes | 20 (58.8) | 74 (76.3) | 0.084 |  | 17 (63.0) | 22 (81.5) | 0.224 | ||
 No | 14 (41.2) | 23 (23.7) |  |  | 10 (37.0) | 5 (18.5) |  | ||
TNBC at the initial onset | Â | Â | Â | Â | Â | Â | Â | ||
 Yes | 30 (88.2) | 70 (72.2) | 0.096 |  | 24 (88.9) | 24 (88.9) | 1.000 | ||
 No | 4 (11.8) | 27 (27.8) |  |  | 3 (11.1) | 3 (11.1) |  | ||
Ki67 ≥ 30% | 29 (85.3) | 85 (87.6) | 0.958 |  | 23 (85.2) | 25 (92.6) | 0.665 | ||
Metastatic sites | Â | Â | Â | Â | Â | Â | Â | ||
 Visceral | 19 (55.9) | 53 (54.6) | 1.000 |  | 13 (48.1) | 15 (55.6) | 0.785 | ||
 Non-visceral | 15 (44.1) | 44 (45.4) |  |  | 14 (51.9) | 12 (44.4) |  | ||
Metastatic sites > 3 | 9 (26.5) | 50 (51.5) | 0.020 |  | 8 (29.6) | 10 (37.0) | 0.773 | ||
Location of metastases | Â | Â | Â | Â | Â | Â | Â | ||
 Brain | 1 (2.9) | 6 (6.2) | 0.779 |  | 0 | 0 | NA | ||
 Bone | 12 (35.3) | 45 (46.4) | 0.356 |  | 8 (29.6) | 8 (29.6) | 1.000 | ||
 Liver | 5 (14.7) | 19 (19.6) | 0.707 |  | 4 (14.8) | 4 (14.8) | 1.000 | ||
 Lung | 15 (44.1) | 41 (42.3) | 1.000 |  | 11 (40.7) | 13 (48.1) | 0.784 | ||
 Lymph node | 25 (73.5) | 70 (72.2) | 1.000 |  | 19 (70.4) | 20 (74.1) | 1.000 | ||
 Adrenal glands | 0 | 2 (2.1) | 0.975 |  | 0 | 0 | NA | ||
 Chest wall | 3 (8.8) | 13 (13.4) | 0.691 |  | 3 (11.1) | 4 (14.8) | 1.000 | ||
(Neo-) Adjuvant therapies | Â | Â | Â | Â | Â | Â | Â | ||
 Paclitaxel/Docetaxel | 20 (58.8) | 63 (64.9) | 0.666 |  | 17 (63.0) | 18 (66.7) | 1.000 | ||
 Anthracyclines | 20 (58.8) | 71 (73.2) | 0.177 |  | 17 (63.0) | 18 (66.7) | 1.000 | ||
 Paclitaxel/Docetaxel and Anthracyclines | 20 (58.8) | 61 (62.9) | 0.830 |  | 17 (63.0) | 18 (66.7) | 1.000 | ||
 Platinum (Cis/Carbo) | 2 (5.9) | 3 (3.1) | 0.833 |  | 2 (7.4) | 1 (3.7) | 1.000 | ||
 Capecitabine | 2 (5.9) | 3 (3.1) | 0.833 |  | 2 (7.4) | 1 (3.7) | 1.000 | ||
Treatment | Â | Â | Â | Â | Â | Â | Â | ||
 anti-PD-1/L1 antibody | 0 | 0 | NA |  | 0 | 0 | NA | ||
 Nab-paclitaxel | 11 (32.4) | 11 (11.3) | 0.011 |  | 6 (22.2) | 5 (18.5) | 1.000 | ||
 Eribulin | 3 (8.8) | 10 (10.3) | 1.000 |  | 2 (7.4) | 2 (7.4) | 1.000 | ||
 Paclitaxel/Docetaxel | 2 (5.9) | 34 (35.1) | 0.002 |  | 2 (7.4) | 1 (3.7) | 1.000 | ||
 Other chemotherapy (Platinum, Capecitabine, Gemcitabine, NVB, etc.) | 24 (70.6) | 80 (82.5) | 0.219 |  | 22 (81.5) | 25 (92.6) | 0.418 | ||
Lines of therapy |  |  |  |  |  |  |  | ||
 1st Line | 6 (17.6) | 53 (54.6) | < 0.001 |  | 6 (22.2) | 6 (22.2) | 1.000 | ||
 2nd+ Line | 28 (82.4) | 44 (45.4) |  |  | 21 (77.8) | 21 (77.8) |  | ||